SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Nickenig, G.
Right arrow Articles by Struijker-Boudier, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickenig, G.
Right arrow Articles by Struijker-Boudier, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers

Georg Nickenig

University of Saarland, Homburg, Germany

Jan Östergren

Karolinska University Hospital, Stockholm, Sweden, jan.ostergren@ karolinska.se

Harry Struijker-Boudier

University of Maastricht, Maastricht, The Netherlands

Targeting the renin-angiotensin-aldosterone system (RAAS), specifically the effector peptide angiotensin II (Ang II), represents a major opportunity for slowing the progression of cardiovascular disease (CVD) and, in turn, reducing the risk of morbidity and mortality. Inhibition of angiotensin-converting enzyme (ACE) and selective blockade of Ang II AT1 receptors are two approaches through which the pathophysiological effects of Ang II can be targeted. Numerous clinical studies have established the benefits of ACE inhibitors P, (ACE-Is) in lessening the morbidity and mortality burden of CVD. There are, however, tolerability concerns associated with ACE-Is, such as angioedema and dry cough. By blocking Ang II at the AT1 receptor level, Ang II receptor blockers (ARBs) provide a more specific and complete blockade of the deleterious effects of Ang II and tend to have more favourable tolerability. A number of clinical trials have shown that ARBs are not only associated with positive outcomes across the CVD continuum but may also have a role in the prevention or delay of diabetes (a major cardiovascular risk factor). Ongoing trials are aiming to define the place of such agents in lessening morbidity and mortality from CVD.

Key Words: Angiotensin II receptor blockers • Renin-angiotensin-aldosterone system • Cardiovascular disease continuum

References

  • Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Burnier M., Brunner HR Angiotensin II receptor antagonists. Lancet 2000;355:637-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Studer R., Reinecke H., Muller B., Holtz J., Just H., Drexler H. Increased angiotensin I converting enzyme gene expression in the failing human heart. J Clin Invest 1994;94:301-10.[Web of Science][Medline] [Order article via Infotrieve]
  • Iwai N., Shimoike H., Kinoshita M. Cardiac reninangiotensin system in the D hypertrophied heart. Circulation 1995;92:2690-6.[Abstract/Free Full Text]
  • Matsubara H. Pathophysiological role of angiotensin II receptor in cardiac and renal diseases. Circ Res 1998; 83:1182-91.[Abstract/Free Full Text]
  • Horuichi M., Akshita M., Dzau VJ Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.[Abstract/Free Full Text]
  • Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. JRAAS 2001;2(suppl 2):S4-S7.
  • The CONSENSUS Investigators. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
  • Flather MD, Yusuf S., Køber L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Roig E., Perez-Villa F., Morales M. et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21:53-7.[Abstract/Free Full Text]
  • Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.[Abstract/Free Full Text]
  • McInnes GT Clinical advantage of valsartan. Cardiology 1999;91(Suppl 1):14-18.[Web of Science][Medline] [Order article via Infotrieve]
  • Gibson GR Enalapril-induced cough. Arch Intern Med 1989;149:2701-03.[Abstract/Free Full Text]
  • Os I., Bratland B., Dahlöf B. et al. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992; 339:372.[Medline] [Order article via Infotrieve]
  • Burnier M. Angiotensin II receptor blockers. Circulation 2001;103:904-12.[Free Full Text]
  • Carey RM, Wang Z.-Q. Siragy HM Role of the angiotensin type II receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-63.[Abstract/Free Full Text]
  • Bauer JH, Reams GP The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995;155:1361-8.[Abstract/Free Full Text]
  • Messerli FH, Weber MA, Brunner HR Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996;156:1957-65.[Abstract/Free Full Text]
  • Pylypchuk GB ACE inhibitor versus angiotensin II blocker induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.[Abstract]
  • Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005;46:137-43.[Abstract/Free Full Text]
  • Dahlöf B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindholm LH, Ibsen H., Borch-Johnsen K. et al. Risk of new-onset diabetes in the Losartan Intervention For End point reduction in hypertension study. J Hypertens 2002;20:1879-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Julius S., Kjeldsen SE, Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31. JR[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kjeldsen SE, Julius S., Weber MA, Stolt P. Main results from VALUE. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney. 2nd ed. Philadelphia, Pa: Elsevier Saunders;2005:376-80.
  • Thurmann PA, Kenedi P., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42.[Abstract/Free Full Text]
  • Malmquist K., Kahan T., Edner M. et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.[Web of Science][Medline] [Order article via Infotrieve]
  • Montalescot G., Collet JP Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005;26:2616-22.[Abstract/Free Full Text]
  • Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Viberti G., Wheeldon NM, for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002;106:672-8.[Abstract/Free Full Text]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Keane WF, Lyle PA Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis 2003;41(Suppl 3):S22-S25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barnett AH, Bain SC, Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.[Abstract/Free Full Text]
  • Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wong M., Staszewsky L., Latini R. et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-5.[Abstract/Free Full Text]
  • Krum H., Carson P., Farsang C. et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6:937-45.[Abstract/Free Full Text]
  • Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]
  • Dickstein K., Kjekshus J., and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • ACC/AHA Task Force. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. J Am Coll Cardiol 2004;44: 671-719.[Free Full Text]
  • ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.[Free Full Text]
  • McMurray JJ, Califf R., Holman R. et al. Cardiologists should care about glucose: most people with cardiovascular disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR [abstract]. Eur Heart J 2004;25(Suppl):239.
  • Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-26A.[Web of Science][Medline] [Order article via Infotrieve]
  • Carson P., Massie BM, McKelvie R. et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Cardiol Fail 2005;11:576-85.[CrossRef]
  • Chaturvedi N., Sjoelie AK, Svensson A., for the DIRECT Programme Study Group. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. JRAAS 2002;3:255-61.[Medline] [Order article via Infotrieve]
  • Sjolie AK, Porta M., Parving HH et al. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005;6:25-32.[Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1 suppl, S1-S7 (2006)
DOI: 10.3317/jraas.2006.017
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Nickenig, G.
Right arrow Articles by Struijker-Boudier, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickenig, G.
Right arrow Articles by Struijker-Boudier, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement